Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is -11.82% lower on its value in year-to-date trading and has touched a low of $2.21 and a high of $19.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PHAT stock was last observed hovering at around $9.58 in the last trading session, with the day’s loss setting it -6.8%.
Currently trading at $2.78M, the stock is 15.91% and 72.98% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.98 million and changing 975127% at the moment leaves the stock 7.77% off its SMA200. PHAT registered 17.61% gain for a year compared to 6-month loss of 28.19%. The firm has a 50-day simple moving average (SMA 50) of $5.521 and a 200-day simple moving average (SMA200) of $8.861825.
The stock witnessed a 131.80% gain in the last 1 month and extending the period to 3 months gives it a 48.75%, and is -12.39% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.17% over the week and 18.11% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 427 employees, a market worth around $666.73M and $81.86M in sales. Profit margin for the company is -422.42%. Distance from 52-week low is 332.13% and -51.55% from its 52-week high. The company has generated returns on investments over the last 12 months (-165.71%).
The EPS is expected to grow by 42.39% this year
193.0 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 88.52% of the company’s shares. The shares outstanding are 69.64M, and float is at 37.85M with Short Float at 29.16%. Institutions hold 84.73% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares valued at $104.13 million. The investor’s holdings represent 17.2637 of the PHAT Shares outstanding. As of 2024-06-30, the second largest holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares valued at $76.89 million to account for 12.7473 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 3.5 million shares representing 5.9715 and valued at over $35.84 million, while INVESCO LTD. holds 5.3681 of the shares totaling 3.14 million with a market value of $32.38 million.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider purchase by Topper James N, the company’s Director. SEC filings show that Topper James N bought 3,780 shares of the company’s common stock on May 21 ’25 at a price of $3.86 per share for a total of $14609.0. Following the purchase, the insider now owns 59403.0 shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on May 14 ’25 that Topper James N (Director) bought a total of 6,300 shares of the company’s common stock. The trade occurred on May 14 ’25 and was made at $3.32 per share for $20919.0. Following the transaction, the insider now directly holds 55623.0 shares of the PHAT stock.
Still, SEC filings show that on May 13 ’25, Topper James N (Director) acquired 1,120 shares at an average price of $3.16 for $3543.0. The insider now directly holds 49,323 shares of Phathom Pharmaceuticals Inc (PHAT).
